Dupixent shows promise for eczema skin barrier in chinese patients
NCT ID NCT05624112
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested the drug dupilumab (Dupixent) in 44 Chinese patients aged 12 to 65 with moderate to severe atopic dermatitis (eczema). The goal was to see if the drug improves skin barrier function by measuring water loss through the skin over 16 weeks. Participants received dupilumab injections and had regular skin tests. The study is complete, but results are not yet published.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dupilumab (Dupixent)
What this could lead to
If successful, this could confirm that dupilumab improves skin barrier function, supporting its use for managing atopic dermatitis.
What could go wrong
This is a small, open-label study with no placebo group, so results may not be definitive. It only looks at a specific measure (water loss) and may not reflect overall symptom improvement.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dermatology Hospital of Southern Medical University (Guangdong Provincial Dermatology Hospital)
Guangzhou, Guangdong, 510091, China